ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

BDSX vs JNJ // RETURN ON INVESTED CAPITAL (ROIC)

Biodesix Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: BDSX 1 — JNJ 7
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: JNJ
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BDSX VS. JNJ) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC BDSX JNJ SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 67.90% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) ACTIVE -35.00% 25.50% -60.50 JNJ /roic <GO>
EV/EBITDA & P/E Valuation — 18.5x — TIE /valuation <GO>
Free Cash Flow Yield -9.02% 2.97% -11.99 JNJ /fcf-yield <GO>
Operating Margin -31.50% 34.70% -66.20 JNJ /operating-margins <GO>
Net Profit Margin -39.90% 28.50% -68.40 JNJ /net-margins <GO>
Revenue Growth (YoY) 24.10% 6.00% +18.10 BDSX /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 5.59 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 8/9 -4.00 JNJ /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 44.0 62.1 -18.14 JNJ /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 1.08 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 23.0x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $260.8M $662.49B -$662.23B JNJ /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR BDSX REV JNJ REV BDSX GROSS % JNJ GROSS % BDSX FCF JNJ FCF
FY 2025 $88.5M $94.19B — 67.9% -$23.5M $19.70B
FY 2024 $71.3M $88.82B — 69.1% -$51.9M $19.84B
FY 2023 $49.1M $85.16B — — -$22.9M $18.96B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BDSX // BETA —
JNJ // BETA 1.08